Orphan Drugs Need Easier, Speedier Approval, Not More Exclusivity, CEO Says

Advocates and drug developers continue to call for an Orphan Drug Act renovation – not to add more years of marketing exclusivity, but to consider allowing easier and cheaper development programs.